Previous 10 | Next 10 |
Syndax Pharmaceuticals (NASDAQ: SNDX ): Q1 GAAP EPS of -$0.56 misses by $0.05 . More news on: Syndax Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
WALTHAM, Mass. , May 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended M...
Syndax Pharmaceuticals (NASDAQ: SNDX ) prices its public offering of ~5.6M common shares at $18 per share. Underwriters' over-allotment is an additional ~833K shares. Closing date is May 4. More news on: Syndax Pharmaceuticals, Inc., Healthcare stocks news, , Stocks on the move, Read...
WALTHAM, Mass. , April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today the pricing of an underwritten public of...
Syndax Pharmaceuticals (NASDAQ: SNDX ) plans to offer common stock, and will grant underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold in the public offering. More news on: Syndax Pharmaceuticals, Inc., Stocks on the move, Read more ...
WALTHAM, Mass. , April 29, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it plans to offer and sell, subject to...
Axsome Therapeutics Reports Positive Alzheimer Results Axsome Therapeutics Inc. ( AXSM ) reported that its lead drug candidate AXS 05 met its primary endpoint in the ADVANCE-1 Phase 2/3 trial. The ADVANCE-1 study was a randomized, double-blind, controlled, trial and had 366 patients suffe...
Shares of Kura Oncology (NASDAQ: KURA) -- a clinical-stage biopharmaceutical company that focuses on developing cancer treatments -- were up by 42.6% as of 1:49 p.m. EDT on Tuesday. The company did not report any news, but its stock is probably riding the wave of Syndax Pharmaceuticals (...
This morning Syndax Pharmaceuticals (NASDAQ: SNDX) updated investors with initial data from a phase 1/2 trial evaluating its leukemia drug, and shares are soaring 55% at 12:05 pm EST on Tuesday. Syndax is a clincial-stage healthcare company developing cancer drugs, including SNDX-5613, a ...
Gainers: Creative Realities (NASDAQ: CREX ) +125% . More news on: Creative Realities, Inc., Syndax Pharmaceuticals, Inc., Kura Oncology, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
14.37%Change Percent:
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia PR Newswire – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review – WALTHAM, Mass. , ...
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...